Turning Cancer Insights into Autoimmune Disease Solutions

It’s remarkable to consider that more than 14 years have passed since the FDA approval of Yervoy (ipilimumab) first ignited what has come to be known as the “immuno oncology revolution,” ushering in a new era in cancer treatment.

Innovations that utilize a patient’s own immune system to fight cancer, including checkpoint inhibitors, CAR-T cell therapies, tumor-infiltrating lymphocytes, and T cell engagers, have since transformed oncology. These treatments offer more effective, durable, and better-tolerated additional options to the highly toxic chemotherapies of the past. The impact from these innovations continues to reverberate throughout the pharmaceutical industry and now appears to be culminating in the next revolution—this time in immunology.